COLON CARCINOMA IN RENAL TRANSPLANT RECIPIENT- CASE REPORT
Abstract
Renal transplant recipients are prone to
infectious, metabolic and neoplastic complications,
which is the trade off for low
incidence of rejection with potent immunosuppressive
drugs. Malignancy is the
third common cause of death after transplantation.
Normal immunological surveillance
is impaired in transplant recipients
due to the immunosuppressive drugs.
Our patient was a 50 year lady, who had
normal graft function until 9 years post
transplant, presented with disseminated
colon carcinoma
Full Text:
PDFReferences
Briggs JD. Causes of death after
renal transplantation. Nephrol
Dial Transplant 2001; 16:1545-
Caillard S, Agodoa LY, Bohen E
M, Abbott KC. Myeloma Hodgkin
disease and lymphoid leukemia
after renal transplantation: characteristics,
risk factors and prognosis.
Transplantation 2006; 81: 888–
Penn I. Malignancies associated
with renal transplantation. Urology
; 10(Suppl 1): 57-63.
Danpanich E, Kasiske BL. Risk factors
for cancer in renal transplant recipients.
Transplantation 1999; 68: 1859–
Andres A. Cancer incidence after immunosuppressive
treatment following
kidneytransplantation. Crit Rev Oncol
Hematol 2005; 56: 71-85.
Chapman JR, Campistol JM. Malignancy
in renal transplantation: opportunities
with proliferationsignal inhibitors.
Nephrol Dial Transplant 2007;22(suppl
: i1-i3.
Kauffman HM, Cherikh WS, Cheng Y,
Hanto DW, Kahan BD. Maintenanceimmunosuppression
with target-ofrapamycin
inhibitors is associated with a
reduced incidence of denovo malignancies.
Transplantation 2005; 80: 883–889.
Christian M. Malignancy in renal transplantation.
J Am Soc Nephrol 2004; 15:
-1588.
Kidney Disease Improving Global Outcomes
(KDIGO) Transplant work Group.
KDIGO clinicalpractice guideline for the
care of kidney transplant recipients. Am J
Transplant 2009; 9(Suppl 3):S1–S155.
Claire MV, Stephen PM, Margaret RE,
et al. Cancer incidence before and after
kidneytransplantation. JAMA 2006; 296
(23): 2823-2831.
Sjodahl R, Franzen T, Nystrom P.
Primary versus staged resection for
acute obstructingcolorectal carcinoma. Br
J Surg 1992; 79: 685–688.
Kim GP, Sargent DJ, Mahoney
MR, et al. Phase III noninferiority
trial comparing irinotecan withoxaliplatin,
fluorouracil, and leucovorin
in patients with advanced colorectal
carcinoma previouslytreated with
fluorouracil. J Clin Oncol 2009; 27
(17) 2848-54
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University